Company news

Novartis AG news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Novartis delivered sales growth and core margin expansion in Q3; raised FY core operating income guidance

October 27, 2026

Novartis remibrutinib delivered comprehensive disease control in Phase III RMS trials, with proven, robust safety profile

October 23, 2026

Novartis receives European Commission approval for Cosentyx® in polymyalgia rheumatica (PMR)

October 21, 2026

DKSH: Singapore and Novartis Announce Strategic Partnership to Support Access to Ophthalmology Solutions in Singapore

October 8, 2026

Novartis Rhapsido® (remibrutinib) receives FDA approval as first treatment for symptomatic dermographism (SD), expanding its use beyond chronic spontaneous urticaria (CSU)

October 7, 2026

CAS ประกาศความร่วมมือกับ Novartis เพื่อขับเคลื่อนระบบข้อมูลด้านปฏิกิริยาเคมีที่พร้อมรองรับ AI

September 29, 2026

Novartis receives positive CHMP opinion for Cosentyx® in polymyalgia rheumatica (PMR)

September 18, 2026

Sironax Announces Option Exercise and Asset Purchase

September 16, 2026

Novartis provides update on delpacibart etedesiran (del-desiran) Phase III HARBOR study for the treatment of myotonic dystrophy type 1 (DM1)

September 8, 2026

Novartis announces Lp(a)HORIZON Phase III topline results for pelacarsen in patients with elevated Lp(a) and established cardiovascular disease (CVD)

September 4, 2026

Novartis remibrutinib, a high-efficacy oral BTK inhibitor, significantly reduces relapse rates and shows favorable safety profile in Phase III RMS trials

September 1, 2026

Novartis data at ESC Congress 2026 reinforce cardiovascular leadership and showcase progress in next-generation therapies

August 19, 2026

FDA approves Pluvicto for PSMA+ metastatic hormone-sensitive prostate cancer (mHSPC), advancing potential new standard of care across metastatic disease

July 31, 2026

Novartis receives Health Canada approval for (Pr)RHAPSIDO® (remibrutinib tablets) oral treatment for adults with CSU

July 27, 2026

Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed

July 21, 2026

Novartis Fabhalta® (iptacopan) receives FDA traditional approval as first and only complement inhibitor to significantly slow kidney function decline in primary IgAN

July 16, 2026

Sofinnova Partners Announces Myricx Bio Agrees to Be Acquired by Novartis

July 6, 2026

Brandon Capital Announces Agreement for Novartis to Acquire Portfolio Company Myricx Bio to Advance New Class of Cancer Therapeutics

July 6, 2026

Novartis agrees to acquire Myricx Bio, advancing next-generation antibody-drug conjugate innovation with a novel NMTi payload, expanding options for cancer patients

July 6, 2026

Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)

July 2, 2026

Novartis RemIND data at EAACI show Rhapsido® potential as first targeted therapy for chronic inducible urticaria (CIndU)

June 12, 2026

Novartis delpacibart braxlosiran (del-brax) Phase I/II study in facioscapulohumeral muscular dystrophy (FSHD) meets primary biomarker endpoint

June 11, 2026

Novartis to highlight Rhapsido® data across multiple immune-mediated diseases at EAACI Congress 2026

June 8, 2026

Novartis IgAN data in The Lancet show clinically meaningful slowing of kidney function decline with Vanrafia® over 2.5 years

June 4, 2026

Novartis Cosentyx® PMR data in New England Journal of Medicine showed sustained remission vs placebo in twice as many patients

June 3, 2026

Scemblix® continued to show superior efficacy and favorable safety and tolerability profile at week 144 in newly diagnosed CML

June 1, 2026

Novartis data at EULAR 2026 demonstrates momentum for broad immunology portfolio for complex, high unmet need diseases

June 1, 2026

Pluvicto™ demonstrated consistent efficacy across key patient subgroups in metastatic hormone-sensitive prostate cancer

May 31, 2026

New Novartis data at ERA 2026 advance scientific understanding of kidney disease and reinforce portfolio strength

May 26, 2026

Novartis advances RLT innovation and reinforces leadership in prostate cancer, breast cancer and hematology with new data at ASCO and EHA

May 21, 2026

New PSMAddition data show 58% lower risk of PSA progression with Pluvicto® in metastatic hormone-sensitive prostate cancer

May 17, 2026

Novartis breaks ground on Denton, Texas radioligand therapy site; construction now underway across all new US facilities

May 7, 2026

Model N Appoints Thomas Gibbs to Board of Directors

May 5, 2026

Novartis receives Health Canada approval for Fabhalta® oral treatment for adults with C3G

May 1, 2026

Novartis finalizes US manufacturing and R&D expansion plan with seventh new facility

April 30, 2026

Novartis delivered strong growth in priority brands and launches in Q1; FY 2026 guidance reaffirmed

April 28, 2026

Novartis Rhapsido® receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria

April 27, 2026

Novartis receives positive CHMP opinion for Itvisma® for spinal muscular atrophy (SMA)

April 24, 2026

Novartis malaria treatment Coartem® Baby receives WHO prequalification, paving way for greater access for newborns and young infants

April 24, 2026

Novartis announces expansion of community health programs to close gaps in heart disease and cancer care, targeting more than 30 countries by 2030

April 9, 2026

Novartis IgAN data in New England Journal of Medicine show Fabhalta® slowed kidney function decline by 49.3%

March 29, 2026

Excellergy to be acquired by Novartis for up to USD 2 billion to advance potentially first-in-class trifunctional effector cell response inhibitors

March 27, 2026

Novartis agrees to acquire Excellergy, Inc., building on allergy leadership with next-generation anti-IgE innovation

March 27, 2026

Novartis presents new data on early symptom relief and long-term control in complex skin diseases at AAD 2026

March 23, 2026

Novartis agrees to acquire a pan-mutant-selective PI3Kα inhibitor, strengthening its breast cancer pipeline

March 20, 2026

Novartis Cosentyx® receives FDA approval for pediatric patients aged 12+ with moderate to severe hidradenitis suppurativa

March 13, 2026

Novartis shareholders approve all resolutions proposed by the Board of Directors at the 2026 Annual General Meeting

March 6, 2026

Novartis successfully completes acquisition of Avidity Biosciences, strengthening late-stage neuroscience pipeline and advancing xRNA strategy

February 27, 2026

Novartis receives positive CHMP opinion for remibrutinib in chronic spontaneous urticaria (CSU)

February 27, 2026

Novartis to build new radioligand therapy site in Denton, Texas, delivering more next‑generation treatments to patients

February 25, 2026

Older news releases →

Calls

The 5 newest of 26 calls. Every call is listed under its year.

Decks

The 5 newest of 39 decks. Every deck is listed under its year.